Back to News
Market Impact: 0.2
JP Morgan Initiates Coverage of Neurogene at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
JP Morgan initiated coverage of Neurogene with an Overweight recommendation on October 8, 2026. The stock closed at $25.87 on October 7, after a reported 7.01% price decline over the article’s truncated period.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
NGNE0.40
More News
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- Hexagon jumps 3% as J.P. Morgan sees earnings upside from recovering demand
- Cramer’s week ahead: Earnings kick off as banks and chipmakers face big tests
- JPMorgan downgrades DuPont stock rating on recovery outlook
- Jim Cramer's top 10 things to watch in the stock market Friday
- Crown Holdings Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call